Company intelligence / Profile preview

Deadline

Rehovot, Israel

Ownership: Private
Development stage: Other

Overview

Deadline Therapeutics is a biotechnology company focused on developing novel cancer treatments by targeting RNA-binding proteins (RBPs). The company utilizes a proprietary platform to identify and modulate RBPs that are critical for the survival of cancer cells but are not essential for healthy cells. Their approach aims to create a new class of precision oncology drugs that can overcome resistance to current therapies. By focusing on the RNA-protein interface, Deadline seeks to address hard-to-treat cancers and overcome common resistance mechanisms. The company was founded in 2021 and is headquartered in Israel.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Deadline.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deadline.

Explore the full profile